SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-20-067962
Filing Date
2020-06-01
Accepted
2020-06-01 06:28:45
Documents
10
Period of Report
2020-05-29
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2021428-1_8k.htm 8-K 28285
2 EXHIBIT 4.1 tm2021428d1_ex4-1.htm EX-4.1 96487
3 EXHIBIT 5.1 tm2021428d1_ex5-1.htm EX-5.1 26170
4 EXHIBIT 5.2 tm2021428d1_ex5-2.htm EX-5.2 14273
5 EXHIBIT 10.1 tm2021428d1_ex10-1.htm EX-10.1 213686
6 EXHIBIT 99.1 tm2021428d1_ex99-1.htm EX-99.1 9681
7 GRAPHIC tm2021428d1_ex5-1img001.jpg GRAPHIC 2287
8 GRAPHIC tm2021428d1_ex99-1img001.jpg GRAPHIC 4306
9 GRAPHIC tm2021428d1_ex5-2img001.jpg GRAPHIC 2291
10 GRAPHIC tm2021428d1_ex5-2img002.jpg GRAPHIC 9426
  Complete submission text file 0001104659-20-067962.txt   415723
Mailing Address 1000 CONTINENTAL DRIVE SUITE 600 KING OF PRUSSIA PA 19406
Business Address 56 FITZWILLIAM SQUARE DUBLIN L2 2 (610) 816-6640
Nabriva Therapeutics plc (Filer) CIK: 0001641640 (see all company filings)

IRS No.: 000000000 | State of Incorp.: L2 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37558 | Film No.: 20930849
SIC: 2834 Pharmaceutical Preparations